Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
Research output: Contribution to journal › Journal article › Research › peer-review
Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
| Original language | English |
|---|---|
| Journal | Scientific World Journal |
| Volume | 2012 |
| Pages (from-to) | 170496 |
| Number of pages | 4 |
| ISSN | 2356-6140 |
| DOIs | |
| Publication status | Published - 2012 |
ID: 48498667